Email
Password
To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Or registration with your favorite social network

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

Company

AMONETA DIAGNOSTICS

AMONETA DIAGNOSTICS_logo
6
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Huningue, Grand-Est, France

Send a message

English

English

French

AMONETA DIAGNOSTICS Who are we?

Amoneta offers a unique diagnostic test for an unmet, high medical need: Reliable early diagnosis of Alzheimer's Disease.

The test is performed on a minimal blood sample, based on the detection of two complementary biomarkers. The first results show a reliability up to 95% in human subjects, even 100% in animals. The competitive advantages of ADDIA test are (1) the ease of implementation, rapid, minimally invasive, effective laboratory routine and inexpensive, (2)...

See more

Amoneta offers a unique diagnostic test for an unmet, high medical need: Reliable early diagnosis of Alzheimer's Disease.

The test is performed on a minimal blood sample, based on the detection of two complementary biomarkers. The first results show a reliability up to 95% in human subjects, even 100% in animals. The competitive advantages of ADDIA test are (1) the ease of implementation, rapid, minimally invasive, effective laboratory routine and inexpensive, (2) reliability, compared to all existing competitor tests (3) repeatability, the fact that it can be repeated without bias, unlike neuropsychological tests.

Compared to competitor companies developing blood biomarkers, Amoneta is ahead as it is the only company so far with clinical development on 1024 patients being recruited in its late stage clinical studies.

Our latest news

Our history

Start in 2014

  • 2014

    Amoneta Diagnostics SAS is founded by Firalis SA and SODIV.

  • 2015

    ADDIA Project proposal has been awarded with a "Seal of Excellence" and a 5 Mio € grant by the EU.

  • 2016

    Amoneta obtained approvals from various ethic committee for its ADDIA multicentric clinical study.

  • Jan-2017

    Amoneta launched its ADDIA multicentric study aiming to do the proof-of-performance of its test.

  • Mar-2018

    Strasbourg Hospital finalized recruitments for the Chronobiological study (part of ADDIA Program).

to be continued ...